| |
High volume hydration Mg-
|
High volume hydration Mg+
|
Low volume hydration Mg+
|
|---|
| |
(n = 41)
|
(n = 27)
|
(n = 17)
|
|---|
|
Age (year)
|
66 (63 to 70)
|
66 (57 to 70)
|
63 (62 to 67)
|
|
Gender Male (%)
|
31 (75.6)
|
18 (66.6)
|
16 (94.1)
|
|
BSA (m2)
|
1.7 ± 0.2
|
1.6 ± 0.2
|
1.7 ± 0.2
|
|
PS (ECOG): 0 (%)
|
5 (12.1)
|
4 (14.8)
|
5 (29.4)
|
|
1 (%)
|
36 (87.8)
|
23 (85.2)
|
12 (70.6)
|
|
Stage I (%)
|
0 (0)
|
1 (3.7)
|
0 (0)
|
|
II (%)
|
5 (12.2)
|
3 (11.1)
|
3 (17.6)
|
|
III (%)
|
25 (61.0)
|
15 (55.5)
|
8 (47.1)
|
|
IV (%)
|
9 (22.0)
|
7 (25.9)
|
6 (35.3)
|
|
Others (%)
|
2 (4.9)
|
1 (3.7)
|
0 (0)
|
|
Histology Adenocarcinoma (%)
|
17 (41.5)
|
13 (48.1)
|
11 (64.7)
|
|
Squamous cell carcinoma (%)
|
11 (26.8)
|
7 (25.9)
|
5 (29.4)
|
|
Small cell carcinoma (%)
|
9 (22.0)
|
6 (22.2)
|
1 (5.9)
|
|
Others (%)
|
4 (9.8)
|
1 (3.7)
|
0 (0)
|
|
Serum Hb (g/dl)
|
13.3 (12.0 to 14.8)
|
13.6 (12.8 to 14.8)
|
13.3 (12.7 to 14.9)
|
|
Serum Alb (g/dl)
|
4.0 ± 0.4
|
4.1 ± 0.4
|
3.9 ± 0.4
|
|
Cisplatin dose (mg/m2)
|
80 (80 to 80)
|
80 (75 to 80)
|
80 (75 to 80)
|
|
Regular use drug
| | | |
|
NSAIDs (%)
|
10 (24.4)
|
2 (7.4)
|
2 (11.7)
|
|
Mg for purgative (%)
|
14 (34.1)
|
8 (29.6)
|
5 (29.4)
|
|
Combined anticancer agent (%)
| | | |
|
VNB
|
22 (53.7)
|
13 (48.1)
|
10 (58.8)
|
|
PEM
|
3 (7.3)
|
6 (22.2)
|
5 (29.4)
|
|
CPT-11
|
3 (7.4)
|
1 (3.7)
|
0
|
|
VP-16
|
8 (19.5)
|
6 (22.2)
|
1 (5.9)
|
|
GEM
|
2 (4.9)
|
0
|
1 (5.9)
|
|
S-1
|
1 (2.4)
|
1 (3.7)
|
0
|
|
AMR
|
1 (2.4)
|
0
|
0
|
|
DTX
|
1 (2.4)
|
0
|
0
|
- Continuous variables are expressed as mean ± standard deviation or median (interquartile range). Categorical variables are expressed as number (proportion).
- BSA, body surface area; PS, performance status; Hb, hemogulobin; Alb, albumin; NSAIDs, non-steroid anti-Inflammatory drugs; Non-Steroidal Anti-Inflammatory Drugs; Mg for purgative, Mg-contating medications for purgative; VNB, vinorelbine; PEM, pemetrexed; CPT-11, irinotecan; VP-16, etoposide; GEM, gemcitabine; AMR, amurubicin; DTX, docetaxel.
